Top neuroscientists say Biogen's experimental drug for Alzheimer's disease appears to have promise as clinical treatment that slows the disease's attack on the brain -- despite the drug's complicated backstory and conflicting data from two clinical trials. If approved by the FDA, it could become the first drug to attack the dementia-causing disease itself and not just its symptoms.
Biogen’s Potential New Drug For Alzheimer’s Disease Gets Cautiously Optimistic Review Following Presentation
Fredrick Kunkle, Washington Post: Local
Thu, 12/05/2019 - 4:44pm
RELATED ARTICLES
- Sunday helped establish the new month as windy April
Gusts reached more than 40 mph during breezy hours. More - Md. juvenile justice bills seek to ‘treat children as children’
Goal is to reduce the chances of recidivism in adulthood. More - PM Update: Clear and chilly tonight. Clouds return for Monday.
With clear skies and diminishing winds, temperatures will drop close to the freezing mark tonight o More - D.C. walking group helps women connect after two years of loneliness
Members of City Girls Who Walk DC are making up for lost time after the pandemic hindered their ability to make new friendships organically. More - Van hits Metrobus in D.C., killing van driver and injuring his child
The crash occurred at about 1:20 a.m. Sunday at Martin Luther King Jr. Avenue SE and Highview Place SE, authorities said. More - D.C. police investigate death of man found at Eastern Market station
The man was found unresponsive Saturday evening and pronounced dead at the scene, police say. More
BING NEWS:
- Alzheimer’s drug’s impact limited in U.S.
More than 6 million Americans, and millions more worldwide, have Alzheimer’s disease, the most common cause of dementia. There’s no cure, but Leqembi clears ...
04/14/2024 - 6:16 pm | View Link - Eisai, Biogen say Alzheimer’s drug succeeds in slowing cognitive decline
Since Alzheimer’s is a disease of aging, an estimated 85 percent of patients eligible for the drug are covered by the government plan. The number of Americans living with Alzheimer’s is ...
04/11/2024 - 1:00 pm | View Link - EU drug regulator does not refer to Eisai-Biogen Alzheimer's drug in meeting notes
The drug, sold as Leqembi in the United States has been under review in Europe since January 2023. It gained traditional approval in the United States last year and is also approved in other ...
03/22/2024 - 12:46 pm | View Link - EU regulator delays decision on Eisai-Biogen Alzheimer's drug
opens new tab Alzheimer's disease drug that was expected ... hold an oral hearing this week to discuss the drug, lecanemab, which has been under review in Europe since January 2023.
03/22/2024 - 3:30 am | View Link - EU delays decision on Eisai-Biogen Alzheimer’s drug
The European Union's drug ... the review. Lecanemab has been approved in China, Japan and the U.S. as a treatment of mild cognitive impairment and mild dementia due to Alzheimer's disease.
03/22/2024 - 2:50 am | View Link - More
Welcome to Wopular
Wopular is an
online newspaper rack,
giving you a summary view of the top headlines from the top news sites.
Senh Duong (Founder)
Wopular,
MWB,
RottenTomatoes
MoviesWithButter : Our Sister Site
- "Expendables 4" Starts Shooting This Fall, Says Randy Couture at the Arnold Sports Festival more
- “Expendables 4” Gets Funding Interest from “Ip Man 3” Financier more
- "Ip Man 3" Distributor Suspected of Box Office Fraud, Parent Company Loses $200M in Market Cap more
- Yen Targets "Ip Man 4" for 2018 Release; Discusses Film with Director, Producer more
- "Ip Man 3" Shatters Expectations with $72M Opening [China Box Office] more